JP2015510926A5 - - Google Patents

Download PDF

Info

Publication number
JP2015510926A5
JP2015510926A5 JP2015501032A JP2015501032A JP2015510926A5 JP 2015510926 A5 JP2015510926 A5 JP 2015510926A5 JP 2015501032 A JP2015501032 A JP 2015501032A JP 2015501032 A JP2015501032 A JP 2015501032A JP 2015510926 A5 JP2015510926 A5 JP 2015510926A5
Authority
JP
Japan
Prior art keywords
composition
bcp
schizophrenia
treat
patient suffering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015501032A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015510926A (ja
JP6326563B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2013/052182 external-priority patent/WO2013140342A1/en
Publication of JP2015510926A publication Critical patent/JP2015510926A/ja
Publication of JP2015510926A5 publication Critical patent/JP2015510926A5/ja
Application granted granted Critical
Publication of JP6326563B2 publication Critical patent/JP6326563B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015501032A 2012-03-19 2013-03-19 β−カリオフィレンとCB2受容体アゴニストを用いた精神病の治療 Expired - Fee Related JP6326563B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261612411P 2012-03-19 2012-03-19
US61/612,411 2012-03-19
PCT/IB2013/052182 WO2013140342A1 (en) 2012-03-19 2013-03-19 Treatment of schizophrenia using beta-caryophyllene and cb2 receptor agonists

Publications (3)

Publication Number Publication Date
JP2015510926A JP2015510926A (ja) 2015-04-13
JP2015510926A5 true JP2015510926A5 (https=) 2016-05-12
JP6326563B2 JP6326563B2 (ja) 2018-05-23

Family

ID=49221922

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015501032A Expired - Fee Related JP6326563B2 (ja) 2012-03-19 2013-03-19 β−カリオフィレンとCB2受容体アゴニストを用いた精神病の治療

Country Status (4)

Country Link
US (4) US20150051299A1 (https=)
EP (1) EP2827846B1 (https=)
JP (1) JP6326563B2 (https=)
WO (1) WO2013140342A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150051299A1 (en) 2012-03-19 2015-02-19 Ariel-University Research And Development Company, Ltd. Treatment of schizophrenia using beta-caryophyllene and cb2 receptor agonists
HK1244715A1 (zh) 2015-03-02 2018-08-17 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
JP6397792B2 (ja) * 2015-04-10 2018-09-26 ポッカサッポロフード&ビバレッジ株式会社 飲料
US20190060300A1 (en) * 2016-03-04 2019-02-28 Sharon Anavi-Goffer Self-Emulsifying Compositions of CB2 Receptor Modulators
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
WO2018060766A2 (en) * 2016-10-02 2018-04-05 Anavi Goffer Sharon Genetic susceptibility diagnosis and treatment of mental disorders
WO2021182538A1 (ja) * 2020-03-10 2021-09-16 学校法人近畿大学 カリオフィレンを含有する剤、組成物及び各種用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072824A1 (en) * 2001-06-01 2004-04-15 Adam Telerman Methods and compositions for the treatment of cancer
US20070154534A1 (en) * 2003-03-12 2007-07-05 Sheitman Brian B Use of secretin in the treatment of schizophrenia
CA2569887A1 (en) * 2004-06-09 2005-12-22 Glaxo Group Limited Pyrrolopyridine derivatives
WO2006017892A1 (en) * 2004-08-16 2006-02-23 Northern Sydney And Central Coast Area Health Service Methods for improving cognitive functioning
BRPI0419105A (pt) * 2004-10-01 2007-12-11 Ache Lab Farmaceuticos Sa usos de cariofilenos ou composições que compreendem cariofilenos, método de tratamento de condições inflamatórias e dores inflamatórias, método de inibição e composição que compreende cariofileno
US7923465B2 (en) * 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
PT1903866E (pt) * 2005-11-07 2016-06-09 Murty Pharmaceuticals Inc Distribuição melhorada de tetra-hidrocanabinol
AU2007245733A1 (en) * 2006-04-27 2007-11-08 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CBX cannabinoid receptor modulators and Potassium channel modulators
US20110028542A1 (en) * 2007-05-31 2011-02-03 Jean Legault Compositions for prevention or treatment of anorexia-cachexia syndrome and uses thereof
KR20110073653A (ko) 2009-12-24 2011-06-30 충북대학교 산학협력단 4-o-메틸호노키올을 유효 성분으로 함유하는 항-불안 예방 및 치료용 의약 조성물
US20150051299A1 (en) 2012-03-19 2015-02-19 Ariel-University Research And Development Company, Ltd. Treatment of schizophrenia using beta-caryophyllene and cb2 receptor agonists
US9486419B2 (en) 2013-04-17 2016-11-08 Ariel-University Research And Development Company CB2 receptor ligands for the treatment of psychiatric disorders
WO2018060766A2 (en) 2016-10-02 2018-04-05 Anavi Goffer Sharon Genetic susceptibility diagnosis and treatment of mental disorders
US20190321355A1 (en) 2016-12-15 2019-10-24 Sharon Anavi-Goffer Treatment of mental, movement and behavioral disorders

Similar Documents

Publication Publication Date Title
JP2015510926A5 (https=)
JP2016539144A5 (https=)
JP2015537003A5 (https=)
AR062886A1 (es) Compuestos de tiazol pirazolopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
JP2011508765A5 (https=)
JP2010535220A5 (https=)
TW201306840A (zh) 投予4-((1r,3s)-6-氯-3-苯基-二氫茚-1-基)-1,2,2-三甲基-哌□反其鹽用於治療精神分裂症的方法
GEP20125379B (en) 2 -pyridine carboxamide derivatives as sodium channel modulators
JP2012524112A5 (https=)
MX2009011619A (es) Formulaciones que contienen clopidogrel y eter sulfoalquilico-ciclodextrina y metodos de uso.
JP2015524444A5 (https=)
HRP20201916T1 (hr) Trifluorometil supstituirani pirazoli kao inhibitori kalikreina u ljudskoj plazmi
IL188643A (en) Derivatives – n (troaryl) –1 – troarylalkyl – 1h – indole – 2– carboxamide, process for the production of derivatives, drug, pharmaceutical composition and use of derivatives for drug production.
HRP20120918T1 (hr) Aminopirazolski spoj
UA107353C2 (en) Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof
NZ569331A (en) COP 1 for treatment of inflammatory bowel diseases
RU2011137131A (ru) Производные 1-аминоалкилциклогексана для лечения тиннитуса, связанного с потерей слуха или незначительной потерей слуха
WO2008006795A3 (en) Indole compounds
JP2010516701A5 (https=)
JP2015510916A5 (https=)
JP2015510928A5 (https=)
MA37455A1 (fr) Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique
PH12017501831A1 (en) Pharmaceutical compositions for oral administration
JP2017520588A5 (https=)
RU2014142025A (ru) Препарат длительного высвобождения для снижения частоты мочеиспускания и способ его применения